Adenovirus release from the infected cell as a key factor for adenovirus oncolysis

Open Gene Therapy Journal

Volumn 3, Issue , 2010, Pages 24-30

  Gros, Alena ^a   Guedan, Sonia ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

Adenovirus; Cell to cell spread; Oncolytic potency; Progeny release

Indexed keywords

AD 337; ADENOVIRUS DEATH PROTEIN; CISPLATIN; DL 250; DL 716; DL 732; E1B PROTEIN; FLUOROURACIL; KD 1; KD 3; LP 11; LP 26; LP 53; ONCOLYTIC ADENOVIRUS; ONYX 201; ONYX 203; PACLITAXEL; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VIRUS PROTEIN; VRX 006; VRX 007; VRX 009; VRX 011;

ADENOVIRUS RELEASE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL DEATH; CELL KILLING; CLINICAL TRIAL; CYTOLYSIS; CYTOPATHOGENIC EFFECT; DNA MODIFICATION; DRUG RELEASE; EXTRACELLULAR MATRIX; GENE DELETION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNOMODULATION; LIVER METASTASIS; NONHUMAN; ONCOLYTIC VIROTHERAPY; POINT MUTATION; PRIORITY JOURNAL; PROGENY; PROMOTER REGION; PROTEIN FUNCTION; TRANSGENE; VIRION;

ADENOVIRIDAE;

EID: 77953783397     PISSN: None     EISSN: 18750370     Source Type: Journal    
DOI: 10.2174/1875037001003020024     Document Type: Article

References (70)

1. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, WoldWS. Tumor-specific, replication-competent adenovirus vectorsoverexpressing the adenovirus death protein. J Virol 2000; 74:6147-55.
2. Sauthoff H, Heitner S, Rom WN, Hay JG. Deletion of theadenoviral E1b-19kD gene enhances tumor cell killing of areplicating adenoviral vector. Hum Gene Ther 2000; 11: 379-88.
3. Wein LM, Wu JT, Kirn DH. Validation and analysis of amathematical model of a replication-competent oncolytic virus forcancer treatment: implications for virus design and delivery.Cancer Res 2003; 63: 1317-24.
4. Wodarz D. Viruses as antitumor weapons: defining conditions fortumor remission. Cancer Res 2001; 61: 3501-7.
5. Doronin K, Kuppuswamy M, Toth K, et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer genetherapy. J Virol 2001; 75: 3314-24.
6. Toth K, Djeha H, Ying B, et al. An oncolytic adenovirus vectorcombining enhanced cell-to-cell spreading, mediated by the ADPcytolytic protein, with selective replication in cancer cells withderegulated wnt signaling. Cancer Res 2004; 64: 3638-44.
7. Gros A, Martinez-Quintanilla J, Puig C, et al. Bioselection of again of function mutation that enhances adenovirus 5 release andimproves its antitumoral potency. Cancer Res 2008; 68: 8928-37.
8. Subramanian T, Vijayalingam S, Chinnadurai G. Genetic identi-fication of adenovirus type 5 genes that influence viral spread. JVirol 2006; 80: 2000-12.
9. Yan W, Kitzes G, Dormishian F, et al. Developing novel oncolyticadenoviruses through bioselection. J Virol 2003; 77: 2640-50.
10. Zhang Y, Schneider RJ. Adenovirus inhibition of cell translationfacilitates release of virus particles and enhances degradation of thecytokeratin network. J Virol 1994; 68: 2544-55.
11. Debbas M, White E. Wild-type p53 mediates apoptosis by E1A,which is inhibited by E1B. Genes Dev 1993; 7: 546-54.
12. Chiou SK, Tseng CC, Rao L, White E. Functional complementa-tion of the adenovirus E1B 19-kilodalton protein with Bcl-2 inthe inhibition of apoptosis in infected cells. J Virol 1994; 68: 6553-66.
13. Querido E, Marcellus RC, Lai A, et al. Regulation of p53 levels bythe E1B 55-kilodalton protein and E4orf6 in adenovirus-infectedcells. J Virol 1997; 71: 3788-98.
14. Pilder S, Logan J, Shenk T. Deletion of the gene encoding theadenovirus 5 early region 1b 21,000-molecular-weight polypeptideleads to degradation of viral and host cell DNA. J Virol 1984; 52:664-71.
15. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, WoldWS. The adenovirus death protein (E3-11.6K) is required at verylate stages of infection for efficient cell lysis and release ofadenovirus from infected cells. J Virol 1996; 70: 2296-306.
16. Tollefson AE, Ryerse JS, Scaria A, Hermiston TW, Wold WS. TheE3-11.6-kDa adenovirus death protein (ADP) is required forefficient cell death: characterization of cells infected with adpmutants. Virology 1996; 220: 152-62.
17. Tollefson AE, Scaria A, Saha SK, Wold WS. The 11,600-MWprotein encoded by region E3 of adenovirus is expressed early butis greatly amplified at late stages of infection. J Virol 1992; 66:3633-42.
18. Lavoie JN, Nguyen M, Marcellus RC, Branton PE, Shore GC.E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway that is not inhibited by zVAD-fmk. J Cell Biol 1998; 140: 637-45.
19. Marcellus RC, Lavoie JN, Boivin D, Shore GC, Ketner G, BrantonPE. The early region 4 orf4 protein of human adenovirus type 5induces p53-independent cell death by apoptosis. J Virol 1998; 72:7144-53.
20. Abou El Hassan MA, van der Meulen-Muileman I, Abbas S, KruytFA. Conditionally replicating adenoviruses kill tumor cells via abasic apoptotic machinery-independent mechanism that resemblesnecrosis-like programmed cell death. J Virol 2004; 78: 12243-51.
21. Ito H, Aoki H, Kuhnel F, et al. Autophagic cell death of malignantglioma cells induced by a conditionally replicating adenovirus. JNatl Cancer Inst 2006; 98: 625-36.
22. Jiang H, Gomez-Manzano C, Aoki H, et al. Examination of thetherapeutic potential of Delta-24-RGD in brain tumor stem cells:role of autophagic cell death. J Natl Cancer Inst 2007; 99: 1410-4.
23. Alonso MM, Jiang H, Yokoyama T, et al. Delta-24-RGD incombination with RAD001 induces enhanced anti-glioma effect viaautophagic cell death. Mol Ther 2008; 16: 487-93.
24. Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR,McNeish IA. Oncolytic adenoviral mutants induce a novel mode ofprogrammed cell death in ovarian cancer. Oncogene 2008; 27:3081-90.
25. Ulasov IV, Tyler MA, Zhu ZB, Han Y, He TC, Lesniak MS.Oncolytic adenoviral vectors which employ the survivin promoterinduce glioma oncolysis via a process of beclin-dependentautophagy. Int J Oncol 2009; 34: 729-42.
26. Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS,Toth K. Oncolytic adenovirus that overproduces ADP andreplicates selectively in tumors due to hTERT promoter-regulatedE4 gene expression. Gene Ther 2005; 12: 1608-17.
27. Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE,Wold WS. Overexpression of the ADP (E3-11.6K) proteinincreases cell lysis and spread of adenovirus. Virology 2003; 305:378-87.
28. Ramachandra M, Rahman A, Zou A, et al. Re-engineeringadenovirus regulatory pathways to enhance oncolytic specificityand efficacy. Nat Biotechnol 2001; 19: 1035-41.
29. Yun CO, Kim E, Koo T, Kim H, Lee YS, Kim JH. ADP-overexpressing adenovirus elicits enhanced cytopathic effect byinduction of apoptosis. Cancer Gene Ther 2005; 12: 61-71.
30. Barton KN, Paielli D, Zhang Y, et al. Second-generationreplication-competent oncolytic adenovirus armed with improvedsuicide genes and ADP gene demonstrates greater efficacy withoutincreased toxicity. Mol Ther 2006; 13: 347-56.
31. Freytag SO, Stricker H, Peabody J, et al. Five-year follow-up oftrial of replication-competent adenovirus-mediated suicide genetherapy for treatment of prostate cancer. Mol Ther 2007; 15: 636-42.
32. Wang Y, Hallden G, Hill R, et al. E3 gene manipulations affectoncolytic adenovirus activity in immunocompetent tumor models.Nat Biotechnol 2003; 21: 1328-35.
33. Bortolanza S, Bunuales M, Alzuguren P, et al. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirusin a permissive tumor model in Syrian hamsters. Cancer Gene Ther2009.
34. Bhat BM, Brady HA, Wold WS. Virus deletion mutants that affecta 3' splice site in the E3 transcription unit of adenovirus 2. Mol CellBiol 1985; 5: 2405-13.
35. Scaria A, Wold WS. Fine-mapping of sequences that suppresssplicing in the E3 complex transcription unit of adenovirus.Virology 1994; 205: 406-16.
36. Tollefson AE, Scaria A, Ying B, Wold WS. Mutations within theADP (E3-11.6K) protein alter processing and localization of ADPand the kinetics of cell lysis of adenovirus-infected cells. J Virol2003; 77: 7764-78.
37. Harrison D, Sauthoff H, Heitner S, Jagirdar J, Rom WN, Hay JG.Wild-type adenovirus decreases tumor xenograft growth, butdespite viral persistence complete tumor responses are rarelyachieved--deletion of the viral E1b-19-kD gene increases the viraloncolytic effect. Hum Gene Ther 2001; 12: 1323-32.
38. Liu TC, Hallden G, Wang Y et al. An E1B-19 kDa gene deletionmutant adenovirus demonstrates tumor necrosis factor-enhancedcancer selectivity and enhanced oncolytic potency. Mol Ther 2004;9: 786-803.
39. Liu TC, Wang Y, Hallden G, et al. Functional interactions ofantiapoptotic proteins and tumor necrosis factor in the context of areplication-competent adenovirus. Gene Ther 2005; 12: 1333-46.
40. Mi J, Li ZY, Ni S, Steinwaerder D, Lieber A. Induced apoptosissupports spread of adenovirus vectors in tumors. Hum Gene Ther2001; 12: 1343-52.
41. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, ClaymanGL. Growth suppression of human head and neck cancer cells bythe introduction of a wild-type p53 gene via a recombinantadenovirus. Cancer Res 1994; 54: 3662-7.
42. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovariancarcinoma. Oncogene 1996; 12: 1617-23.
43. Nielsen LL, Dell J, Maxwell E, Armstrong L, Maneval D, CatinoJJ. Efficacy of p53 adenovirus-mediated gene therapy againsthuman breast cancer xenografts. Cancer Gene Ther 1997; 4: 129-38.
44. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA.High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinantadenovirus. Cancer Gene Ther 1994; 1: 5-13.
45. Liu Q, Gazitt Y. Adenovirus-mediated delivery of p53 results insubstantial apoptosis to myeloma cells and is not cytotoxic to flow-sorted CD34(+) hematopoietic progenitor cells and normallymphocytes. Exp Hematol 2000; 28: 1354-62.
46. Zhang WW, Alemany R, Wang J, Koch PE, Ordonez NG, Roth JA.Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Hum GeneTher 1995; 6: 155-64.
47. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW. p53-dependentcell death/apoptosis is required for a productive adenovirusinfection. Nat Med 1998; 4: 1068-72.
48. Dix BR, O'Carroll SJ, Myers CJ, Edwards SJ, Braithwaite AW.Efficient induction of cell death by adenoviruses requires bindingof E1B55k and p53. Cancer Res 2000; 60: 2666-72.
49. Royds JA, Hibma M, Dix BR, et al. p53 promotes adenoviralreplication and increases late viral gene expression. Oncogene2006; 25: 1509-20.
50. Sauthoff H, Pipiya T, Heitner S, et al. Late expression of p53 froma replicating adenovirus improves tumor cell killing and is moretumor cell specific than expression of the adenoviral death protein.Hum Gene Ther 2002; 13: 1859-71.
51. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM,Gerritsen WR. Conditionally replicative adenovirus expressing p53exhibits enhanced oncolytic potency. Cancer Res 2002; 62: 6165-71.
52. Geoerger B, Vassal G, Opolon P, et al. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53against human malignant glioma. Cancer Res 2004; 64: 5753-9
53. Geoerger B, van Beusechem VW, Opolon P, et al. Expression ofp53, or targeting towards EGFR, enhances the oncolytic potency ofconditionally replicative adenovirus against neuroblastoma. J GeneMed 2005; 7: 584-94.
54. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling,biology, and potential for cancer therapy. Cytokine Growth FactorRev 2003; 14: 337-48.
55. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity oftumor necrosis factor-related apoptosis-inducing ligand in vivo. NatMed 1999; 5: 157-63.
56. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activityof recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-62.
57. Sova P, Ren XW, Ni S, et al. A tumor-targeted and conditionallyreplicating oncolytic adenovirus vector expressing TRAIL fortreatment of liver metastases. Mol Ther 2004; 9: 496-509
58. Wohlfahrt ME, Beard BC, Lieber A, Kiem HP. A capsid-modified,conditionally replicating oncolytic adenovirus vector expressingTRAIL Leads to enhanced cancer cell killing in humanglioblastoma models. Cancer Res 2007; 67: 8783-90.
59. Qiu S, Ruan H, Pei Z, et al. Combination of Targeting Gene-ViroTherapy with 5-FU enhances antitumor efficacy in malignantcolorectal carcinoma. J Interferon Cytokine Res 2004; 24: 219-30.
60. Pan Q, Liu B, Liu J, Cai R, Wang Y, Qian C. Synergistic inductionof tumor cell death by combining cisplatin with an oncolyticadenovirus carrying TRAIL. Mol Cell Biochem 2007; 304: 315-23.
61. Alemany R, Cascallo M. Oncolytic viruses from the perspective ofthe immune system. Future Microbiol 2009; 4: 527-36.
62. Aghi M, Martuza RL. Oncolytic viral therapies - the clinicalexperience. Oncogene 2005; 24: 7802-16.
63. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS. Immunosuppression enhances oncolytic adenovirus replicationand antitumor efficacy in the Syrian hamster model. Mol Ther2008; 16: 1665-73.
64. Ganesh S, Gonzalez-Edick M, Gibbons D, Van Roey M, Jooss K.Intratumoral coadministration of hyaluronidase enzyme andoncolytic adenoviruses enhances virus potency in metastatic tumormodels. Clin Cancer Res 2008; 14: 3933-41.
65. Ganesh S, Gonzalez Edick M, Idamakanti N, et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survivalof tumor-bearing mice. Cancer Res 2007; 67: 4399-407.
66. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. Relaxinexpression from tumor-targeting adenoviruses and its intratumoralspread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006;98: 1482-93.
67. van Kuppeveld FJ, Hoenderop JG, Smeets RL, et al. Coxsackievirusprotein 2B modifies endoplasmic reticulum membrane and plasmamembrane permeability and facilitates virus release. Embo J 1997;16: 3519-32.
68. Agirre A, Barco A, Carrasco L, Nieva JL. Viroporin-mediatedmembrane permeabilization. Pore formation by nonstructuralpoliovirus 2B protein. J Biol Chem 2002; 277: 40434-41.
69. Gonzalez ME, Carrasco L. Viroporins. FEBS Lett 2003; 552: 28-34.
70. Williams JF.Enhancement of adenovirus plaque formation onHeLa cells by magnesium chloride. J Gen Virol 1970; 9: 251-5.